ClassID:

20353

A61K31/4353 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems

Sub-classes:
Recent Application in this class:
#1
20260152508
2026-06-04

Heteroarylsulfonyl Compounds As USP18 Inhibitors

#2
20260069575
2026-03-12

USE OF APICIDIN COMBINED WITH BEVACIZUMAB IN PREPARING DRUG FOR TREATING CERVICAL CANCER

#3
20260034106
2026-02-05

Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics

#4
20260021051
2026-01-22

PHARMACEUTICAL FORMULATIONS

#5
20260008774
2026-01-08

QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF

#6
20250340545
2025-11-06

TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND, AND USE THEREOF

#7
20250312320
2025-10-09

METHOD AND TREATMENT FOR OSTEOARTHRITIS AND DISEASES OF CHONDROCYTE HYPERTROPHY

#8
20250289828
2025-09-18

MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES

#9
20250268871
2025-08-28

NEW CRYSTAL FORM OF NITROGEN-CONTAINING TRICYCLIC COMPOUND AND USE THEREOF

#10
20250262191
2025-08-21

NEW CRYSTAL FORM OF NITROGEN-CONTAINING TRICYCLIC COMPOUND AND USE THEREOF

#11
20250236629
2025-07-24

MEDIUM- OR MACRO-CYCLIC BENZYL-SUBSTITUTED HETEROCYCLE DERIVATIVES AND RELATED USES

#12
20250186405
2025-06-12

Compound For Use In Treating Narcolepsy

#13
20250101031
2025-03-27

COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF

#14
20250099536
2025-03-27

PRISTINAMYCIN IA AND FLOPRISTIN COMBINATIONS IN TREATING OR PREVENTING BACTERIAL INFECTIONS

#15
20250026740
2025-01-23

QUINOLINONE AMIDE COMPOUNDS AND USES THEREOF

#16
20240409549
2024-12-12

NEW CRYSTAL FORM AND USE OF NITROGENOUS TRICYCLIC COMPOUND

#17
20240262867
2024-08-08

HYBRID CYCLIC LIBRARIES AND SCREENS THEREOF

#18
20240245658
2024-07-25

TAAR1 AND SEROTONIN MODULATORS, AND PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

#19
20240228494
2024-07-11

COMPOUNDS

#20
20240216362
2024-07-04

BENZOTHIAZOLE AND QUINOLINE DERIVATIVES FOR USE IN TREATING KAWASAKI DISEASE

#21
20240207233
2024-06-27

MEDICAMENT

#22
20240059659
2024-02-22

INHIBITORS OF NLRP3 INFLAMMASOME

#23
20240051923
2024-02-15

INHIBITORS OF NLRP3 INFLAMMASOME

#24
20240000756
2024-01-04

METHODS AND COMPOUNDS FOR TREATMENT OF AUTISM SPECTRUM DISORDER

#25
20230201182
2023-06-29

CHEMICAL SYNTHESIS OF CLOPIDOGREL ACTIVE METABOLITES AND DISULFIDE CONJUGATE PRODRUGS

#26
20230158109
2023-05-25

USE OF CD83 IN COMBINATION THERAPIES

#27
20230148448
2023-05-11

BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF

#28
20230129394
2023-04-27

METHODS OF TREATING OR PREVENTING VIRAL INFECTION WITH FLUORINATED AlphaV INTEGRIN ANTAGONISTS

#29
20230115867
2023-04-13

Pemafibrate dosing regimens

#30
20230066830
2023-03-02

METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS IN CANCER STEM CELLS

#31
20230055657
2023-02-23

COMBINATION TREATMENT OF LIVER DISEASES USING INTEGRIN INHIBITORS

#32
20230053946
2023-02-23

COMBINATIONS

#33
20230047905
2023-02-16

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY

#34
20220409643
2022-12-29

ROR Gamma T Inhibitors and Topical Uses Thereof

#35
20220395494
2022-12-15

COMBINATION THERAPY FOR CANCER

#36
20220313624
2022-10-06

SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF

#37
20220296588
2022-09-22

Pemafibrate dosing regimens

#38
20220280484
2022-09-08

NOVEL USE

#39
20220265776
2022-08-25

COMBINATION

#40
20220257627
2022-08-18

Pemafibrate dosing regimens

#41
20220242855
2022-08-04

Fused Imidazole Derivatives as IL-17 Modulators

#42
20220193049
2022-06-23

COMPOSITION COMPRISING CLAY MINERAL COMPLEX FOR PREVENTION, ALLEVIATION, AND TREATMENT OF INFLAMMATORY BOWEL DISEASE, PREPARATION METHOD FOR COMPOSITION, AND METHOD FOR ALLEVIATION AND TREATMENT FOR INFLAMMATORY BOWEL DISEASE

#43
20220175745
2022-06-09

COMPOSITION FOR ORAL ADMINISTRATION WITH CONTROLLED RELEASE PROPERTIES COMPRISING COMPLEX OF CLAY MINERALS, METHOD FOR PREPARING SAME, AND METHOD FOR CONTROLLING RELEASE PROPERTIES

#44
20220144849
2022-05-12

Compounds that participate in cooperative binding and uses thereof

#45
20220127284
2022-04-28

BENZOTHIAZOLE DERIVATIVES AND 7-AZA-BENZOTHIAZOLE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF

#46
20220119413
2022-04-21

Heterocycle amines and uses thereof

#47
20220118026
2022-04-21

MAPC TREATMENT OF BRAIN INJURIES AND DISEASES

#48
20220110982
2022-04-14

MAPC TREATMENT OF BRAIN INJURIES AND DISEASES

#49
20220079951
2022-03-17

BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD

#50
20220016136
2022-01-20

COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISORDERS

#51
20220000799
2022-01-06

SULFUR (VI) FLUORIDE COMPOUNDS AND METHODS FOR THE PREPARATION THEREOF

#52
20210401759
2021-12-30

PHARMACEUTICAL FORMULATIONS

#53
20210317120
2021-10-14

Compositions, uses and methods for making them

#54
20210299185
2021-09-30

MAPC TREATMENT OF BRAIN INJURIES AND DISEASES

#55
20210221809
2021-07-22

Azaindole derivatives and their use as ERK kinase inhibitors

#56
20210188914
2021-06-24

Hybrid cyclic libraries and screens thereof

#57
20210113477
2021-04-22

PHARMACEUTICAL FORMULATIONS

#58
20210093624
2021-04-01

Chemical synthesis of clopidogrel active metabolites and disulfide conjugate prodrugs

#59
20210052598
2021-02-25

COMPOSITIONS AND METHODS FOR TREATING CANCER

#60
20210030928
2021-02-04

Cross-linked fatty acid-based biomaterials

#61
20210008031
2021-01-14

SUPER-OXIDE DISMUTASE MIMETICS

#62
20200397719
2020-12-24

Sulfur (VI) fluoride compounds and methods for the preparation thereof

#63
20200347074
2020-11-05

Compounds that participate in cooperative binding and uses thereof

#64
20200283384
2020-09-10

Antibacterial compounds and methods of use thereof

#65
20200268683
2020-08-27

Arylfluorosulfate compounds and methods

#66
20200230106
2020-07-23

Methods for treating diseases and nerve injuries

#67
20200216468
2020-07-09

Heterocycle amines and uses thereof

#68
20200113873
2020-04-16

MEDICAMENT

#69
20200069662
2020-03-05

Antifibrotic compounds and uses thereof

#70
20190389911
2019-12-26

Hybrid cyclic libraries and screens thereof

#71
20190350864
2019-11-21

PHARMACEUTICAL FORMULATIONS

#72
20190328704
2019-10-31

SUPER-OXIDE DISMUTASE MIMETICS

#73
20190169203
2019-06-06

Nitrogen-containing tricyclic compounds and uses thereof in medicine

#74
20190167604
2019-06-06

ARYLFLUOROSULFATE COMPOUNDS AND METHODS

#75
20190125830
2019-05-02

Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration

#76
20190054053
2019-02-21

Fatty-acid based particles

#77
20190031610
2019-01-31

Antibacterial compounds and methods of use thereof

#78
20190029972
2019-01-31

Sulfur(VI) fluoride compounds and methods for the preparation thereof

#79
20180311299
2018-11-01

EFFICACY OF AN ANTI-C5 ANTIBODY IN THE PREVENTION OF ANTIBODY MEDIATED REJECTION IN SENSITIZED RECIPIENTS OF A KIDNEY TRANSPLANT

#80
20180298031
2018-10-18

Heterocycle amines and uses thereof

#81
20180298012
2018-10-18

Octahydropyrrolopyrroles their preparation and use

#82
20180296609
2018-10-18

MAPC treatment of brain injuries and diseases

#83
20180273544
2018-09-27

Compounds that participate in cooperative binding and uses thereof

#84
20180271992
2018-09-27

Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51

#85
20180256604
2018-09-13

Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors

#86
20180222942
2018-08-09

Hybrid cyclic libraries and screens thereof

#87
20180170923
2018-06-21

Compounds for the treatment of cancer

#88
20180117093
2018-05-03

MAPC treatment of brain injuries and diseases

#89
20180086713
2018-03-29

CGAS in systemic lupus erythematosus (SLE)

#90
20180050132
2018-02-22

Cross-linked fatty acid-based biomaterials

#91
20180030003
2018-02-01

Tricyclic compounds and uses thereof in medicine

#92
20170368139
2017-12-28

Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration

#93
20170327514
2017-11-16

Flap modulators

#94
20170196985
2017-07-13

Sulfur(VI) fluoride compounds and methods for the preparation thereof

#95
20170079963
2017-03-23

1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy

#96
20170015673
2017-01-19

Bromodomain inhibitors

#97
20170007686
2017-01-12

Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods

#98
20160347767
2016-12-01

Heterocycle amines and uses thereof

#99
20160324816
2016-11-10

Fatty-acid based particles

#100
20160311912
2016-10-27

ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF

#101
20160263085
2016-09-15

Super-oxide dismutase mimetics

#102
20160199461
2016-07-14

Treatment of synucleinopathies

#103
20160176866
2016-06-23

4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof

#104
20160115203
2016-04-28

Hybrid cyclic libraries and screens thereof

#105
20160030405
2016-02-04

1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy

#106
20150353579
2015-12-10

Triazine derivatives

#107
20150353526
2015-12-10

Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors

#108
20150299198
2015-10-22

Inhibitors of the renal outer medullary potassium channel

#109
20150291587
2015-10-15

Tricyclic compound

#110
20150238506
2015-08-27

FUSED HETEROCYCLIC COMPOUND AND USE THEREOF

#111
20150218175
2015-08-06

THIADIAZOLE ANALOGS THEREOF AND METHODS FOR TREATING SMN-DEFICIENCY-RELATED-CONDITIONS

#112
20150209482
2015-07-30

Cross-linked fatty acid-based biomaterials

#113
20150174149
2015-06-25

Compositions including triciribine and methods of use thereof

#114
20150141353
2015-05-21

Methods for treating HCV

#115
20150080401
2015-03-19

Triazine derivatives

#116
20150050325
2015-02-19

7-(piperazin-1-yl)-5H-[1,3,4]thiadiazolo[3,2-A]pyrimidin-5-ones for the treatment of thrombotic disorders

#117
20150038521
2015-02-05

Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as parp and tubulin polymerization inhibitors

#118
20150038438
2015-02-05

ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE

#119
20150025106
2015-01-22

Thermogel formulation for combination drug delivery

#120
20150011002
2015-01-08

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

#121
20140371234
2014-12-18

Antifibrotic compounds and uses thereof

#122
20140357663
2014-12-04

1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy

#123
20140271949
2014-09-18

Composition and method for preventing, reducing, alleviating or treating idiopathic vomiting

#124
20140256795
2014-09-11

Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration

#125
20140228320
2014-08-14

Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors

#126
20140206861
2014-07-24

Antioxidant small molecules aimed at targeting metal-based oxidative stress in neurodegenerative disorders

#127
20140194418
2014-07-10

Bicyclic carboxamide inhibitors of kinases

#128
20140155387
2014-06-05

Anti-inflammation compounds

#129
20140155379
2014-06-05

Heterocycle amines and uses thereof

#130
20140142165
2014-05-22

Therapeutic particles suitable for parenteral administration and methods of making and using same

#131
20140128425
2014-05-08

Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use

#132
20140088067
2014-03-27

Tazobactam arginine compositions

#133
20140073581
2014-03-13

Hybrid cyclic libraries and screens thereof

#134
20140010821
2014-01-09

Use of CD83 in combination therapies

#135
20130303553
2013-11-14

Fused heterocyclic compounds

#136
20130287767
2013-10-31

Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof

#137
20130217720
2013-08-22

Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators

#138
20130177549
2013-07-11

Treatment of synucleinopathies

#139
20130064892
2013-03-14

Cellulosic gel material as a pharmaceutical excipient

#140
20130040979
2013-02-14

CCR1 INHIBITORS USEFUL FOR THE TREAMENT OF MULTIPLE MYELOMA AND OTHER DISORDERS

#141
20130035326
2013-02-07

BIARYL COMPOUNDS AND METHODS OF USE THEREOF

#142
20130030017
2013-01-31

QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS

#143
20130030016
2013-01-31

QUINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS

#144
20120283288
2012-11-08

1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy

#145
20120264741
2012-10-18

PHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREVENTING, TREATING, OR REVERSING NEURONAL DYSFUNCTION

#146
20120252794
2012-10-04

ANALGESIC COMBINATION OF OPIOID ANALGESIC AND CYCLOOXYGENASE-2 INHIBITOR

#147
20120245223
2012-09-27

USE OF GYMNODIMINE, ANALOGUES AND DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF NEURODEGENERATIVE DISEASES ASSOCIATED WITH TAU AND B-AMYLOID

#148
20120202841
2012-08-09

Topical compositions comprising ascomycins

#149
20120165312
2012-06-28

Fused heterocyclic compound and use thereof

#150
20120129841
2012-05-24

CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES

#151
20120108623
2012-05-03

BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN

#152
20120093917
2012-04-19

METNASE AND INTNASE INHIBITORS AND THEIR USE IN TREATING CANCER

#153
20120087979
2012-04-12

Extended-release oral dosage forms for poorly soluble amine drugs

#154
20120065166
2012-03-15

Bone Modulators And Methods Therewith

#155
20120027757
2012-02-02

Compositions and methods for treating cancer

#156
20110319394
2011-12-29

Fused heterocyclic compounds

#157
20110275621
2011-11-10

HIV integrase inhibitors

#158
20110269715
2011-11-03

ABNORMAL CANNABIDIOLS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE

#159
20110263622
2011-10-27

Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors

#160
20110201640
2011-08-18

Tricyclic compound

#161
20110190271
2011-08-04

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

#162
20110184010
2011-07-28

Method of treating mantle cell lymphoma

#163
20110160190
2011-06-30

CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS

#164
20110105552
2011-05-05

BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN

#165
20110091459
2011-04-21

IMIDAZOLE MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M3

#166
20110065657
2011-03-17

Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

#167
20110053934
2011-03-03

COMPOUNDS AND METHODS OF TREATMENT

#168
20110038851
2011-02-17

Treatment of synucleinopathies

#169
20100310570
2010-12-09

MAPC TREATMENT OF BRAIN INJURIES AND DISEASES

#170
20100256178
2010-10-07

Super-oxide dismutase mimetics

#171
20100249090
2010-09-30

NEUROTHERAPEUTIC COMPOSITION AND METHOD THEREFOR

#172
20100233232
2010-09-16

Fatty-acid based particles

#173
20100226986
2010-09-09

Therapeutic particles suitable for parenteral administration and methods of making and using same

#174
20100216826
2010-08-26

Polymorphisms in voltage-gated sodium channel alpha 1-subunit as markers for therapy selection

#175
20100204322
2010-08-12

METHOD OF TREATING AUTOIMMUNE DISEASES

#176
20100204270
2010-08-12

Quinoline Derivatives as Antibacterial Agents

#177
20100204201
2010-08-12

HIV integrase inhibitors

#178
20100179132
2010-07-15

Carboline derivatives useful in the inhibition of angiogenesis

#179
20100173927
2010-07-08

Beloxepin and analogs for the treatment of pain

#180
20100104642
2010-04-29

Hydrophilic foam and pharmaceutical dosage form employing the same

#181
20100098691
2010-04-22

COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT

#182
20100093691
2010-04-15

TOPICAL FORMULATIONS

#183
20100093611
2010-04-15

COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES

#184
20100009973
2010-01-14

Integrase Inhibitors 3

#185
20100008890
2010-01-14

MAPC therapeutics without adjunctive immunosuppressive treatment

#186
20090297576
2009-12-03

Local Delivery of PAR-1 Antagonists to Treat Vascular Complications

#187
20090286823
2009-11-19

CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders

#188
20090252704
2009-10-08

THERAPIES FOR COGNITION AND LEARNING ENHANCEMENT

#189
20090233959
2009-09-17

BELOXEPIN AND ANALOGS FOR THE TREATMENT OF PAIN

#190
20090227574
2009-09-10

Administration of carboline derivatives useful in the treatment of cancer and other diseases

#191
20090208552
2009-08-20

Cross-linked fatty acid-based biomaterials

#192
20090181966
2009-07-16

PGD2 receptor antagonists for the treatment of inflammatory diseases

#193
20090180986
2009-07-16

Treating unwanted ocular conditions using an ascomycin macrolactam

#194
20090131402
2009-05-21

Fused heterocyclic compound and use thereof

#195
20090105262
2009-04-23

Bridged polycyclic compound based compositions for coating oral surfaces in humans

#196
20090088373
2009-04-02

USE OF COMPOSITIONS TO ENHANCE INNATE IMMUNE RESPONSE

#197
20090069277
2009-03-12

Compounds and compositions for treating infection

#198
20090054399
2009-02-26

HIV integrase inhibitors

#199
20090048234
2009-02-19

Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction

#200
20090043378
2009-02-12

Biocompatible Polymer System for Extended Drug Release

#201
20090029987
2009-01-29

Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices

#202
20090022806
2009-01-22

Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof

#203
20080312199
2008-12-18

Treatments of therapy resistant diseases and drug combinations for treating the same

#204
20080306098
2008-12-11

Pharmacokinetics of protease inhibitors and other drugs

#205
20080279961
2008-11-13

TELOMERE TARGETING AGENTS AS STEM CELLS DIRECTED TREATMENTS

#206
20080234267
2008-09-25

Compounds and Methods of Treatment

#207
20080207679
2008-08-28

Glutathione peroxidase mimetics for the treatment of dermatoses

#208
20080200447
2008-08-21

Neurotherapeutic compositions and method

#209
20080194500
2008-08-14

Semi-fluorinated block copolymers for delivery of therapeutic agents

#210
20080182899
2008-07-31

ASSOCIATION OF BETA3 RECEPTOR AGONIST AND MONOAMINE REUPTAKE INHIBITORS, PHARMACEUTICAL COMPOSITION AND THERAPEUTIC USE THEREOF

#211
20080152618
2008-06-26

Identification and use of agents that modulate oncogenic transcription agent activity

#212
20080146535
2008-06-19

Compositions comprising carbacephem beta-lactam antibiotics and beta-lactamase inhibitors

#213
20080108603
2008-05-08

COMBINATION THERAPY FOR THE TREATMENT OF PAIN

#214
20080070886
2008-03-20

Anti-cancer combinations

#215
20080070849
2008-03-20

Anti-cancer combinations

#216
20080070848
2008-03-20

Anti-cancer combinations

#217
20080070847
2008-03-20

Anti-cancer combinations

#218
20080050427
2008-02-28

Analgesic combination of tramadol and meloxicam

#219
20080027045
2008-01-31

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

#220
20080021020
2008-01-24

2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents

#221
20080009484
2008-01-10

2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents

#222
20070287700
2007-12-13

Polycyclic agents for the treatment of respiratory syncytial virus infections

#223
20070254878
2007-11-01

Administration of carboline derivatives useful in the treatment of cancer and other diseases

#224
20070249596
2007-10-25

Abnormal cannabidiols as agents for lowering intraocular pressure

#225
20070249523
2007-10-25

Neurotherapeutic composition and method therefor

#226
20070244083
2007-10-18

Polymorphisms in voltage-gated sodium channel α 1-subunit as markers for therapy selection

#227
20070238725
2007-10-11

Therapeutic combinations for the treatment or prevention of psychotic disorders

#228
20070238649
2007-10-11

Agents for Regulating Adiponectin Receptor Expression

#229
20070225317
2007-09-27

RSV POLYMERASE INHIBITORS

#230
20070197654
2007-08-23

COMBINATION OF A CB1 RECEPTOR ANTAGONIST AND OF A PRODUCT WHICH ACTIVATES DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN, THE PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF PARKINSON'S DISEASE

#231
20070191412
2007-08-16

Analgesic combination of oxycodone and celecoxib

#232
20070191330
2007-08-16

Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases

#233
20070185150
2007-08-09

Therapeutic methods

#234
20070167411
2007-07-19

Compositions for treating angina

#235
20070078513
2007-04-05

Controllable drug releasing gradient coatings for medical devices

#236
20070060637
2007-03-15

Anti-cancer combinations

#237
20060199795
2006-09-07

Receptor agonists

#238
20060178437
2006-08-10

Method of treating autoimmune diseases

#239
20060178359
2006-08-10

Tricyclic compound, process for producing the same, and use

#240
20060106061
2006-05-18

PGD2 receptor antagonists for the treatment of inflammatory diseases

#241
20060083754
2006-04-20

Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases

#242
20060058279
2006-03-16

Topical compositions comprising ascomycins

#243
20060030626
2006-02-09

Method of treating autoimmune diseases

#244
20050282849
2005-12-22

Carboline derivatives useful in the treatment of cancer

#245
20050250846
2005-11-10

Non-peptide GnRH agents, pharmaceutical compositions and methods for their use

#246
20050239814
2005-10-27

RSV polymerase inhibitors

#247
20050209250
2005-09-22

Therapeutic combinations of atypical antipsychotics with corticotropin releasing factor antagonists

#248
20050119482
2005-06-02

Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors

#249
20050118202
2005-06-02

Solid compositions containing compounds unstable to oxygen and method for stabilization thereof

#250
20050113403
2005-05-26

Method of treating mantle cell lymphoma

#251
20050113398
2005-05-26

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

#252
20050004095
2005-01-06

Carbacephem β-lactam antibiotics